Wells Fargo raised the firm’s price target on Cencora to $249 from $236 and keeps an Equal Weight rating on the shares. The firm says results in Q3 were solid, with upside vs. consensus in U.S. Healthcare as Cencora continues to generate growth solidly above LRP levels. The company raised fiscal 2024 EPS guidance by 1.5%, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR: